Stand Up To Cancer takes new approach to multiple myeloma focusing on precursor conditions
Share

IMAGE: Stand Up To Cancer Logo. view more 

view more 

Credit: Stand Up To Cancer

CHICAGO – April 15, 2018 — Stand Up To Cancer announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease.

The SU2C Multiple Myeloma Dream Team will be led by Irene Ghobrial, MD, associate professor of medicine at Dana-Farber Cancer Institute (DFCI) in Boston and co-director of the Center for the Prevention of Progression of Blood Cancers at DFCI, with Ivan M. Borrello, MD, associate professor of oncology at Johns Hopkins University School of Medicine and director of the Cell Therapy and GMP Biologics Core at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as co-leader.

“We tell people with precursor conditions that we will ‘watch and wait’ until it turns into multiple myeloma, with multiple tumors that can potentially cause organ damage,” Dr. Ghobrial said. “That’s like telling people with breast cancer or colon cancer that we are not going to do anything until the cancer metastasizes throughout the body.”

“We want to change that,” she said.

The announcement of the

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD